Business Wire

H2SITE

17.11.2022 09:01:40 CET | Business Wire | Press release

Share
H2SITE inaugurates the first production plant for palladium alloy membranes to obtain hydrogen

Hydrogen takes a new step as a for the energy transition thanks to H2SITE, which has launched the world's first membrane manufacturing plant to obtain hydrogen from ammonia or methanol, and separate hydrogen from low concentration gas blends. The new facility will industrialize the production of membranes, the technological heart of H2SITE, used in the construction of hydrogen production reactors and separators. Similar membranes made of palladium alloys had been so far very costly, fragile, and difficult to manufacture and scale. H2SITE has managed to overcome these obstacles.

Located in Loiu (Biscay Region, Spain), the new H2SITE plant has a production capacity of tens of thousands of membranes per year. For its construction, H2SITE has invested more than 3 million euros, which it plans to double in the coming years to increase production capacity.

“Once the first production line has been validated, our objective is to significantly increase the capacity of the plant, vertically integrate the manufacturing process of the membrane and build new plants to tackle new markets,” according to Andrés Galnares, CEO of H2SITE. "Our objective is to significantly increase the number of membranes produced each year for the next 3 years, which entails continuing to invest in production assets similar to those we have already installed and increasing their level of automation to further reduce our costs.”

In 2022, H2SITE has booked orders of more than 5 million euros. Galnares assures that the goal is to double that figure over the next year, reaching a workforce of more than 50 professionals.

Asier Rufino, CEO of TECNALIA Ventures and President of H2SITE, states that "at TECNALIA we have been working for 20 years on the development and scaling up of hydrogen technologies its entire value chain: production, distribution, transport, storage and end uses. Together with the Technical University of Eindhoven (TU/e), the technology H2SITE leverages on was created. Today, H2SITE has scaled the process, has industrialized it, and is managing to reduce its cost to be able to develop new use cases”.

This plant reflects the success of more than 10 years of collaboration initiated by TECNALIA and TU/e and supported by the Public Administration. H2SITE brings it to a new level with the industrialization of a disruptive process thanks to the help of investors who believe that technology is a critical enabler for the energy transition, such as ENGIE New Ventures, Breakthrough Energy Ventures, EQUINOR Ventures and institutional investors from the Basque Country Capital Riesgo País Vasco and Seed Capital Bizkaia. Along with the team that we have created, we cannot wish for better partners at this time," says Galnares.

The membrane separators and reactors will help provide hydrogen with high purity and limited cost, with focus on hard to abate industry sectors and heavy land and maritime mobility.

H2SITE is currently hiring in Europe. To learn more, follow H2SITE on LinkedIn.

About H2SITE

H2SITE was created in 2019 and has an exclusive technology of reactors separators for the conversion of different raw materials into hydrogen, among which are ammonia, methanol or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration.

https://www.h2site.eu/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005287/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye